



Published in final edited form as:

Diabetologia. 2022 March ; 65(3): 477–489. doi:10.1007/s00125-021-05635-9.

Multi-ethnic GWAS and fine-mapping of glycaemic traits identify novel loci in the PAGE Study

Carolina G. Downie¹, Sofia F. Dimos¹, Stephanie A. Bien², Yao Hu², Burcu F. Darst³, Linda M. Polfus^{3,4}, Yujie Wang¹, Genevieve L. Wojcik⁵, Ran Tao^{6,7}, Laura M. Raffield⁸, Nicole D. Armstrong⁹, Hannah G. Polikowsky¹⁰, Jennifer E. Below¹⁰, Adolfo Correa¹¹, Marguerite R. Irvin⁹, Laura J. F. Rasmussen-Torvik¹², Christopher S. Carlson², Lawrence S. Phillips^{13,14}, Simin Liu^{15,16}, James S. Pankow¹⁷, Stephen S. Rich¹⁸, Jerome I. Rotter¹⁹, Steven Buyske²⁰, Tara C. Matise²¹, Kari E. North¹, Christy L. Avery¹, Christopher A. Haiman³, Ruth J. F. Loos²², Charles Kooperberg², Mariaelisa Graff¹, Heather M. Highland¹

¹Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

²Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

³Department of Preventive Medicine, Center for Genetic Epidemiology, University of Southern California, Los Angeles, CA, USA

⁴Ambry Genetics, Aliso Viejo, CA, USA

⁵Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

⁶Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

⁷Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA

⁸Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

⁹Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA

¹⁰Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

¹¹Department of Medicine, Jackson Heart Study, University of Mississippi Medical Center, Jackson, MS, USA

¹²Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

© Carolina G. Downie, cdownie@live.unc.edu.

Contribution statement All authors participated in the conception or design of the work, drafting the article or revising it for critically important content, and gave final approval of the version to be published. GLW, AC, MRI, LJFRT, CSC, SL, JSP, SSR, JIR, KEN, CLA, CAH, RJFL, CK, MG and HMH contributed to data collection. CGD, SFD, YH, YW, RT, LMR, NDA, HGP, CLA, MG and HMH contributed to data analysis. CGD, SAB, BFD, LMP, GLW, LMR, JEB, LJFRT, LSP, SSR, JIR, SB, TCM, KEN, CLA, RJFL, MG and HMH contributed to data interpretation. CGD and HMH are the guarantors of this work and are responsible for the integrity of the work as a whole.

Supplementary Information The online version contains peer-reviewed but unedited supplementary material available at <https://doi.org/10.1007/s00125-021-05635-9>.

¹³Atlanta VA Medical Center, Decatur, GA, USA

¹⁴Department of Medicine, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA

¹⁵Department of Medicine, Division of Endocrinology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA

¹⁶Department of Epidemiology, Brown School of Public Health, Providence, RI, USA

¹⁷Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA

¹⁸Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

¹⁹Department of Pediatrics, Genome Outcomes, The Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

²⁰Department of Statistics, Rutgers University, Piscataway, NJ, USA

²¹Department of Genetics, Rutgers University, Piscataway, NJ, USA

²²The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Abstract

Aims/hypothesis—Type 2 diabetes is a growing global public health challenge. Investigating quantitative traits, including fasting glucose, fasting insulin and HbA_{1c}, that serve as early markers of type 2 diabetes progression may lead to a deeper understanding of the genetic aetiology of type 2 diabetes development. Previous genome-wide association studies (GWAS) have identified over 500 loci associated with type 2 diabetes, glycaemic traits and insulin-related traits. However, most of these findings were based only on populations of European ancestry. To address this research gap, we examined the genetic basis of fasting glucose, fasting insulin and HbA_{1c} in participants of the diverse Population Architecture using Genomics and Epidemiology (PAGE) Study.

Methods—We conducted a GWAS of fasting glucose ($n = 52,267$), fasting insulin ($n = 48,395$) and HbA_{1c} ($n = 23,357$) in participants without diabetes from the diverse PAGE Study (23% self-reported African American, 46% Hispanic/Latino, 40% European, 4% Asian, 3% Native Hawaiian, 0.8% Native American), performing transethnic and population-specific GWAS meta-analyses, followed by fine-mapping to identify and characterise novel loci and independent secondary signals in known loci.

Results—Four novel associations were identified ($p < 5 \times 10^{-9}$), including three loci associated with fasting insulin, and a novel, low-frequency African American-specific locus associated with fasting glucose. Additionally, seven secondary signals were identified, including novel independent secondary signals for fasting glucose at the known *GCK* locus and for fasting insulin at the known *PPP1R3B* locus in transethnic meta-analysis.

Conclusions/interpretation—Our findings provide new insights into the genetic architecture of glycaemic traits and highlight the continued importance of conducting genetic studies in diverse populations.

Keywords

Fine-mapping; Genome-wide association study; Glucose; Glycaemic traits; HbA_{1c}; Insulin; Transethnic population

Introduction

Type 2 diabetes is a growing public health challenge, affecting approximately 14.6% of the US population [1] and expected to double in prevalence in the next two decades [2–4]. Investigating the genetic architecture of quantitative traits, including fasting glucose, fasting insulin and HbA_{1c}, that serve as early markers of type 2 diabetes progression may lead to a deeper understanding of type 2 diabetes aetiology. For example, prior genome-wide association studies (GWAS) of glycaemic traits identified novel loci in genes and pathways related to glucose metabolism, circadian rhythm regulation, and cell proliferation and development [5, 6], as well as erythrocyte characteristics that can influence HbA_{1c} [7].

Despite the success of prior glycaemic trait GWAS, which have identified nearly 600 loci [5, 6, 8–11], most of these findings were identified in populations primarily of European ancestry. Such limited ancestral diversity reduces our ability to map novel loci [12–18]. Additionally, locus characterisation and fine-mapping can be improved through multi-ethnic studies that increase sample size and leverage differences in linkage disequilibrium (LD) structure between diverse populations [19–22].

This study examined the genetic architecture of fasting glucose, fasting insulin and HbA_{1c} in participants of the diverse Population Architecture using Genomics and Epidemiology (PAGE) Study [23]. We aimed to identify novel genetic loci and independent secondary association signals at previously identified regions and characterise these loci through transethnic fine-mapping.

Methods

Ethics statements

Approval by the Institutional Review Boards was obtained for each participating cohort. Informed consent was obtained from all participants, and the study was conducted in accordance with the principles of the Declaration of Helsinki.

Study population

This study included adults without diabetes who self-identified as African American (AA), Hispanic/Latino (HA), Asian (ASN), Native Hawaiian (HI), Native American (NA), European (EA) or other race/ethnicity, enrolled in the Atherosclerosis Risk in Communities (ARIC) study, the Ichan Mount Sinai School of Medicine's BioMe Biobank (BioMe), the Coronary Artery Risk Development in Young Adults Study (CARDIA), the Multiethnic

Cohort (MEC) Study, the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and the Women's Health Initiative (WHI) (see electronic supplementary material [ESM] Methods for details). These studies were part of the PAGE Study consortium, an NIH-funded effort to characterise the genetic architecture of complex traits among historically underrepresented populations through large-scale genetic epidemiology research [23].

In this paper, we stratified populations based on self-identified race/ethnicity due to historical reasons (e.g. genotyping datasets and study recruitment) and in recognition of the shared lived experiences of people based on self-identified grouping. To address confounding by population stratification, we included ancestral principal components in our models. We conducted two main analyses: transethnic analyses in the entire population; and analyses stratified by self-identified race/ethnicity. Participants who self-identified as 'other race/ethnicity' were included in all transethnic analyses but because of lack of power due to small sample sizes, no population-specific analyses for this group are presented.

Trait measurement

Fasting glucose and fasting insulin concentrations (fasting > 8 h) were measured using standard assays at baseline visits; for all cohorts except HCHS/SOL, HbA_{1c} was measured at a subsequent visit. Glycaemic trait measurements among individuals with type 2 diabetes reflect their current glycaemic control, which is influenced by their access and adherence to medical treatment; therefore, individuals were excluded from analysis if they reported a previous diabetes diagnosis or fasting glucose concentrations consistent with diabetes (> 7.0 mmol/l). Because HbA_{1c} was not measured at the same time point as fasting glucose and fasting insulin in most cohorts and was only added as a diagnostic criterion for diabetes in 2009 [24], after the majority of data were collected, individuals with HbA_{1c} > 48.0 mmol/mol (6.5%) were not excluded from the study population. However, for HbA_{1c} analyses, individuals with extreme HbA_{1c} values (HbA_{1c} > 65.0 mmol/mol [8.1%]) were excluded. Individuals with BMI > 70 kg/m² were also excluded for all traits.

Contributing samples were genotyped using multiple platforms (ESM Methods, ESM Table 1). A total of 53,426 samples were genotyped on the MEGA array, which was specifically designed to increase variant coverage across multiple ethnic groups [25, 26]. Additionally, 28,477 participants with fasting glucose measurements, 12,296 participants with HbA_{1c} measurements and 26,965 participants with fasting insulin measurements from ARIC, BioMe, CARDIA, MEC and WHI were previously genotyped using either Illumina or Affymetrix arrays within each individual study/stratum. All studies used standard quality control filters (ESM Table 1). Ancestral principal component analysis was conducted to evaluate and adjust for population substructure, as previously described in Wojcik et al [26].

Statistical analyses

Fasting glucose concentrations, natural-log-transformed fasting insulin concentrations, and HbA_{1c} measurements were each adjusted for age at trait measurement, sex, age × sex interaction, BMI (kg/m²), smoking status, self-reported race/ethnicity and study centre (see ESM Methods for details of covariate measurements), after which residuals were computed and inverse-normally transformed within each genetic dataset (e.g. population-specific for

ARIC or substudy for WHI). In sensitivity analyses, models were estimated excluding BMI. Association analyses for each dataset were performed using SUGEN version 8.10 (<https://github.com/dragontaoran/SUGEN>), which implemented a generalised estimating equation method that accounts for relatedness, while adjusting for ten ancestral principal components [27]. Subsequently, fixed-effects models with inverse variance weighting were used to pool dataset-specific variant effect estimates and their SEs across populations as well as within populations using METAL version 2011-03-25 (<http://csg.sph.umich.edu/abecasis/Metal/download/>), after applying genomic control correction [28]. Variants with an effective $n < 30$ or an imputation $R^2 < 0.4$ within a given dataset were excluded from meta-analysis. To account for testing of multiple traits across multiple ancestries, we defined novel loci as those in which the lead variant reached a genome-wide significance threshold of $p < 5.0 \times 10^{-9}$, as done previously [26], and were located more than 500 KB from any previously established loci for the given glycaemic trait.

Fine-mapping

To identify independent secondary signals, stepwise conditional analyses were performed for the transethnic meta-analysis results, conditioning on the most significant variants (known and novel) identified in our GWAS and applying genomic control correction. After conditioning on the top genome-wide significant ($p < 5 \times 10^{-9}$) variant, variants identified within a 1 MB region of the variant with a p value $< 5.0 \times 10^{-8}$ were considered significant, independent signals. These conditional analyses were repeated, adding in the conditional lead variants until no variant had a conditional p value less than the locus-specific significance ($p < 5.0 \times 10^{-8}$). To determine whether identified secondary signals at known loci were independent from known secondary signals, we also conditioned on known variants reported in the literature.

We subsequently performed fine-mapping of novel primary analysis loci and independent secondary loci using FINEMAP version 1.4_x86_64 (<http://www.christianbenner.com>) [29]. All variants within ± 1 MB of each novel primary and independent secondary variants were included for fine-mapping, restricting to variants with a stratum specific effective $n > 30$ and imputation $R^2 > 0.4$. If variants demonstrated population-specific significance, a population-specific LD matrix was constructed; for all other variants with genome-wide significance in the transethnic meta-analysis, a combined ancestry LD matrix was constructed by computing population-specific LD matrices and subsequently weighting by population sample size. We then computed the posterior probabilities of k causal variants at each reported locus and constructed a 95% credible set (CS). LocusZoom plots [30] of the CS top variants were generated to visualise the signals identified at each locus.

Replication

Replication of novel loci was performed under a common analysis plan; variant proxies in high LD (D' and $r^2 > 0.9$ in the population of interest) were used if the variant of interest was not genotyped or well-imputed in the following four multi-ethnic studies: Jackson Heart Study (JHS); Cameron County Hispanic Cohort (CCHC); Reasons for Geographical And Racial Differences in Stroke (REGARDS) Study; and Multi-Ethnic Study of Atherosclerosis (MESA). Additionally, published summary statistics from the China Health and Nutrition

Survey (CHNS) cohort [31] and an analysis of individuals of EA ancestry from Lagou et al and the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) [32] were also included for replication analyses (ESM Methods). We used the R package MetaSubtract version 1.60 (<https://cran.r-project.org/web/packages/MetaSubtract/>) [33] to remove overlapping EA ARIC cohort results from the Lagou et al summary statistics before their inclusion in replication (ESM Methods). A maximum of $n = 8459$, $n = 92,432$, $n = 3406$ and $n = 6476$ AA, EA, HA and ASN participants, respectively, were identified for replication of fasting glucose, fasting insulin and HbA_{1c} novel variants. Replication data were not available for HI and NAM populations. Significance was determined using Bonferroni correction (0.05/number of significant novel independent signals). All replication results were meta-analysed in transethnic and population-specific analyses, using METAL [28].

Functional annotation

Finally, to characterise the putative functionality of variants, we performed bioinformatic follow-up for all novel primary and independent secondary variants, as well as the top variants identified in each fine-mapping CS. We used the UCSC Genome Browser Islet Regulome tracks [34–36], which include data on chromatin classes, cytokine-induced regulatory elements and enhancer hubs in both adult human islets and pancreatic progenitors. Additionally, we created a custom UCSC Genome Browser analysis hub of important regions (e.g. enhancer and repressor activities, DNase I hypersensitive sites [DHS] and transcribed regions) in the pancreas and insulin-responsive tissues, including skeletal muscle, liver and adipose tissue, using GTE_x [37] and Roadmap Epigenome Project [38] data.

Results

Study overview

After exclusions, a total of 52,267, 23,357 and 48,395 participants were available for fasting glucose, HbA_{1c} and fasting insulin GWAS, respectively (ESM Table 2), of which collectively over half were either self-reported AA or HA (maximum 23% AA, 46% HA, 40% EA, 4% ASN, 3% HI, 0.8% NAM). The mean age of participants was 54.5 years and they were overweight (mean \pm SD BMI 28.0 ± 5.7), with a greater representation of female participants (72%). Glycaemic trait distributions were similar across studies and self-reported race/ethnic groups, with mean \pm SD fasting glucose levels ranging from 4.5 ± 0.5 mmol/l to 5.5 ± 0.6 mmol/l, HbA_{1c} levels ranging from 34.0 ± 3.5 (5.3%) mmol/mol to 38.6 ± 3.2 (5.7%) mmol/mol and fasting insulin levels ranging from 32.3 ± 19.7 pmol/l to 80.9 ± 59.0 pmol/l.

Identification of significant loci

In the transethnic meta-analysis, we identified a total of 13, 13 and 11 genome-wide significant ($p < 5.0 \times 10^{-9}$) loci for fasting glucose, HbA_{1c} and fasting insulin, respectively (Fig. 1 and ESM Table 3, ESM Fig. 1). Several loci and, in some cases, several top variants were shared across glycaemic traits: *G6PC2* for fasting glucose and HbA_{1c} (shared top variant: rs560887); *GCKR* for fasting glucose and fasting insulin (shared top variant:

rs1260326); *SLC2A2* for fasting glucose and HbA_{1c} (shared top variant: rs1879442); and *GCK* for fasting glucose and HbA_{1c}. Effect estimates for significant variants were generally consistent across populations (Fig. 2 and ESM Fig. 1), although statistical significance varied, often in accordance with minor allele frequency (MAF) and/or sample size.

Three of the 34 significant loci identified in transethnic GWAS were novel (\pm 500 KB from a known variant) at time of analysis (January 2020) and were associated with fasting insulin: the *VEGFA* (also known as *MVCD1*, *VEGF* or *VPF*) locus on chromosome 6 (lead variant rs9472142, $p = 5.56 \times 10^{-10}$); the *CASC8/CASC21* (also known as *CARLO1*, *CARLo-1*, *LINC00860*, *CARLO2*, *CARLo-2* or *LINC01244*) locus on chromosome 8 (lead variant rs35131928, $p = 2.70 \times 10^{-9}$); and the *PTEN* (also known as 10q23del, *BZS*, *CWS1*, *DEC*, *GLM2*, *MHAM*, *MMAC1*, *PTEN1*, *PTENbeta* or *TEPI*) locus on chromosome 10 (lead variant rs10887773, $p = 4.55 \times 10^{-10}$) (Table 1, Figs 1, 2). Wide variation in MAF was observed across populations for lead variants at these three novel loci, particularly for rs9472142 at the *VEGFA* locus (MAF range 0.12–0.36) and rs10887773 at the *PTEN* locus (MAF range 0.10–0.37). Effect estimates were generally directionally consistent across populations (Fig. 2). We also identified a fourth novel locus associated with fasting glucose in the population-specific meta-analysis of self-identified African Americans: the *LRRC37A5P* (also known as *C9orf29*) locus on chromosome 9 (lead variant rs571025325, $p_{AA} = 4.58 \times 10^{-9}$) (Table 1, Figs 1, 2), with a MAF of 0.0037.

Replication of lead variants at four novel loci

Replication of lead variants or proxy variants at the four potentially novel loci was performed through transethnic meta-analysis of independent AA (n range 1311–4986), ASN (n range 667–5809), EA (n range 1054–97,348) and HA (n range 1189–2217) cohorts, with EA fasting insulin results from published summary statistics from Lagou et al contributing the largest sample size. Lead variants for all three novel fasting insulin loci showed directionally consistent effects, although considerable effect attenuation was observed. The *PTEN* lead variant was significant at the Bonferroni-corrected significance level of $p = 0.0125$ ($\alpha = 0.05/4$ signals) in independent transethnic meta-analysis and the other two fasting insulin loci showed suggestive significance, particularly *CASC8/CASC21* ($p = 0.0174$) (Fig. 2 and ESM Table 4). The fourth locus (fasting glucose, *LRRC37A5P*), which was observed only in AA-specific meta-analysis, did not show evidence of replication ($p = 0.62$), although only 41 of the 5110 replication dataset participants were expected to carry at least one copy of the minor allele (ESM Table 4). Furthermore, in Chen et al's [39] recently published glycaemic traits GWAS, our *VEGFA*, *PTEN* and *CASC8/CASC21* lead variants showed significance in transethnic (*VEGFA* and *PTEN*), EA-specific (*VEGFA*, *PTEN*) and East Asian-specific (*PTEN*, *CASC8/CASC21*) meta-analyses; however, these results are not an independent replication as they contain overlapping data from the ARIC, BioMe, WHI, HCHS/SOL and several replication cohorts used here (ESM Table 4).

Secondary analyses at known glycaemic trait loci

Through stepwise conditional analysis, we identified seven significant secondary signals at known glycaemic trait loci, including two previously unreported fasting glucose (*GCK* [also known as *FGQTL3*, *GK*, *GLK*, *HHF3*, *HK4*, *HKIV*, *HXKP*, *LGLK*, *MODY2* or *PNDM1*],

rs55908146) and fasting insulin (*PPP1R3B* [also known as *GL*, *PPP1R4* or *PTG*], rs330941) secondary signals that remained significant after conditioning upon known variants (Table 2 and ESM Table 5). Wide variation in MAF was observed across populations for both novel independent secondary signals rs330941 (MAF range 0.22–0.49) and rs55908146 (MAF range 0.15–0.32) (Table 2).

Fine-mapping

To identify the most likely causal variant(s) for the four putatively novel loci and two novel independent secondary signals, we subsequently utilised FINEMAP to estimate the number of causal variants per locus and generate a 95% CS for each causal variant. For three of the four novel loci (*LRRC37A5P*, *CASC8/CASC21*, *PTEN*) we estimated one causal variant at each locus ($k = 1$) (Table 3); at these loci, the top variants in our GWAS analyses (rs571025325, rs35131928, rs10887773) were identified as the variants most likely to be causal, although with varying posterior probabilities of being the top causal variant (range 0.06–0.79) (ESM Tables 6, 7, 8). The broad range of posterior probabilities by locus reflects the size of the LD block. For the fourth novel locus (*VEGFA*), the highest posterior probability was observed for $k = 2$ causal variants, with our top GWAS variant rs9472142 identified as the top variant in CS *VEGFA1* (Table 3 and ESM Table 9); the top variant in CS *VEGFA2* (rs6910726) was just under the significance threshold in our stepwise conditional analysis, with $p = 4.20 \times 10^{-6}$ (ESM Table 5).

For the two novel independent secondary signals, the highest posterior probabilities were estimated for $k = 2$ (*PPP1R3B*) and $k = 4$ (*GCK*) causal variants (Table 3). Because we did not perform any LD pruning, we identified CSs containing many variants in high LD with each other, and therefore low individual posterior probabilities of being the top causal variant in each CS. For example, at the *PPP1R3B* locus, for the variants in CS_{*PPP1R3B1*}, the posterior probabilities of being the top causal variant range between 0.11 and 0.26 (ESM Table 10). The top three variants in CS_{*PPP1R3B2*}, including the most significant variant from our conditional analysis, rs330941, are in high LD with each other but not the CS_{*PPP1R3B1*} variants, and posterior probabilities for these three variants range from 0.24 to 0.37 (ESM Table 10). The novel *GCK* secondary signal rs55908146 was among the top five variants in CS_{*GCK3*}, all of which had a probability of being the top variant in CS_{*GCK3*} of about 0.10, additionally suggesting an LD block (ESM Table 11). LocusZoom plots of the loci with more than one CS showed that the CSs have little shared LD (ESM Fig. 2).

Functional annotation

We performed bioinformatic follow-up of the novel primary loci and known loci with independent secondary signals using the UCSC Genome Browser Islet Regulome tracks [34–36] and a custom UCSC analysis hub of important regions (e.g. enhancer and repressor activities, DHS and transcribed regions) in the pancreas and insulin-responsive tissues including skeletal muscle, liver and adipose tissue. However, functional annotation of the top variants in the fine-mapping CSs for each loci did not indicate a clear potential mechanism through which variants may act; gene expression in the GTEx dataset [40] showed ubiquitous levels of expression across tissues for most of the loci, and human

pancreatic islet chromatin state data showed chromatin state markers of expression in the general regions of many of the loci (data not shown).

Discussion

Examining the genetic architecture of glycaemic traits in a diverse study, we identified three novel (at time of analysis, January 2020) fasting insulin loci shared across populations and a fourth low-frequency fasting glucose locus specific to self-identified AAs. Additionally, we identified two previously unreported independent secondary signals in the *PPP1R3B* and *GCK* loci associated with fasting insulin and fasting glucose, respectively. These results emphasise the continued need for more GWAS in diverse populations to assess the genetic heterogeneity of complex diseases.

While this paper was under review, Chen et al and the MAGIC consortium published a large-scale transancestry analysis of glycaemic traits, aggregating GWAS data from up to 281,416 individuals without diabetes [39]. They identified the novel fasting insulin-associated *PTEN* locus identified here ($r^2 = D' = 1$ between our identified variant rs10887773 and Chen et al's variant rs12769346), as well as a fasting insulin variant in the *VEGFA* locus. However, after conditioning on Chen et al's top variant (rs998584), our identified *VEGFA* top variant remained genome-wide significant ($p < 5 \times 10^{-9}$). Additionally, there was low LD between the *VEGFA* variants ($r^2_{\text{PAGE rs9472142 and MAGIC rs998584}} = 0.03$, $D'_{\text{PAGE rs9472142 and MAGIC rs998584}} = 0.35$); we note that rs9472152, which was contained within both of our *VEGFA* fine-mapping 95% CSs, is located near rs998584, with $r^2_{\text{rs9472125 and MAGIC rs998584}} = 0.01$ and $D'_{\text{rs9472125 and MAGIC rs998584}} = 0.61$ between the two variants, as calculated from the PAGE combined ancestry LD. The independent fasting insulin and fasting glucose secondary signals we identified in the *PPP1R3B* and *GCK* loci were not among the variants identified at these loci by Chen et al.

Although there was overlap in the cohorts in our PAGE data and in Chen et al, including ARIC, BioMe, WHI and HCHS/SOL, in the PAGE Study much of our contributing genetic data from these cohorts were newly genotyped on the MEGA array, which was specifically designed to increase variant coverage across multiple ancestry groups [25, 26]. Additionally, the distribution of ancestry groups varied across the two analyses: PAGE data had a higher percentage of non-EA participants (% non-EA range 60.0% [fasting insulin] to 62.4% [fasting glucose]) than Chen et al, in which approximately 30% of participants were non-EA. While the PAGE Study's statistical power is diminished by a smaller sample size, due to the increased ancestral diversity and finer genotyping on the MEGA array, we identified two loci not identified by Chen et al and one that was reported by Chen et al [39]. Both approaches provide complementary information on the genetic architecture of glycaemic traits in diverse populations.

The three novel fasting insulin loci identified via transethnic meta-analysis (*VEGFA*, *CASC8/CASC21* and *PTEN*) and the novel fasting glucose AA-specific locus (*LRR37A5P*) harbour genes with biologically plausible roles in insulin signalling and beta cell function. *VEGFA* has been associated with type 2 diabetes [41], waist/hip ratio [42, 43] and erythrocyte traits [44, 45]. Novel variant rs9472142, in CS *VEGFA1*, is in high LD (r^2_{EA}

= 0.97) with an identified *VEGFA* type 2 diabetes variant (rs9472138), supporting an early role of this signal prior to type 2 diabetes onset [22]. Mouse models have also demonstrated that *VEGFA* signalling is necessary for pancreas specification and differentiation and plays important roles in pancreatic islet blood vessel maintenance and blood flow [46]. *CASC8/CASC21* are cancer susceptibility genes and have not been previously associated with insulin or type 2 diabetes, although the *CASC8* locus has been associated with BMI-adjusted waist/hip ratio in individuals of African ancestry [47]. The low probability for any single variant identified in fine-mapping CS1 for *CASC8/CASC21* indicates an LD block or haplotype for this locus. *PTEN* is involved in the negative regulation of insulin signalling [48] and has been associated with type 2 diabetes [41, 49]. A low probability for any single variant in fine-mapping CS^{*PTEN*}1 also indicates a likely LD block or haplotype for this locus. Although several variants in our final novel locus, *LRRC37A5P*, have previously shown suggestive significance ($p < 1.0 \times 10^{-6}$) in association with diastolic BP in a transethnic meta-analysis of the metabolic syndrome [50], this locus has not previously been associated with fasting glucose. The pseudogene *LRRC37A5P* is next to the *PTGR1* gene encoding an enzyme involved in the inactivation of chemotactic factor, leukotriene B4, which is associated with insulin resistance and obesity [51, 52].

Fine-mapping of known fasting insulin and fasting glucose *PPP1R3B* and *GCK* loci containing novel independent secondary signals yielded results consistent with our stepwise conditional analyses. Multiple CSs, including those containing our identified secondary signals, were predicted for each locus. *PPP1R3B* contributes to insulin signalling through an insulin–Akt–protein phosphatase 1 regulatory subunit 3G (PPP1R3G)–protein phosphatase 1 regulatory subunit 3B (PPP1R3B) regulatory axis, in which PPP1R3B binds to dephosphorylated glycogen synthase (GS), thus relaying insulin signals for hepatic glycogen synthesis [53]. Rare *PPP1R3B* missense variants may increase the risk of type 2 diabetes, possibly through altered GS function and altered lipid metabolism [54]. *GCK* encodes the enzyme glucokinase, which acts to maintain glucose homeostasis and has been previously associated with fasting glucose and type 2 diabetes [5, 11, 14, 55–58]. Specific *GCK* mutations also cause Mendelian disease phenotypes including MODY2 and permanent neonatal diabetes mellitus (PNDM) [59–61]. Continuing to identify the spectrum of natural variation across populations of genes that alter risk for glycaemic traits and type 2 diabetes will enable improvements in risk prediction models for diverse populations.

Strengths of this study include the large study size and representation of multiple ancestrally, ethnically and racially diverse populations, including HA and AA populations, which shoulder a large burden of hyperglycaemia and type 2 diabetes in the USA and historically have been understudied in genetic epidemiology research. However, because the greatest proportion of participants were from HA, AA and EA populations, this study was limited in its ability to detect associations specific to East Asian, South Asian, HI and NAM populations. Additionally, our transethnic fine-mapping approach utilised a combined ancestry LD matrix that was constructed by computing population-specific LD matrices and subsequently weighting by population sample size. This weighted LD matrix approach is limited by the fact that it ‘averages’ LD patterns across populations, thus potentially missing ancestry-specific LD differences. Nevertheless, we applied this approach because it accounts for potentially more than two causal variants at a given loci. Developing computationally

scalable fine-mapping methods that leverage ancestry-specific LD patterns while accounting for more than two causal variants is an area of active research.

Furthermore, only the fasting insulin association at the *PTEN* locus replicated in a transethnic meta-analysis of several multi-ethnic studies, although both the *VEGFA* and *CASC8/CASC21* loci showed suggestive significance. Our inability to replicate several identified loci likely reflects the increasing limitations of replication in large-scale ‘mega-biobank’ studies, since meta-analysis of multiple small independent replication studies, as performed here, may be underpowered [62]. Furthermore, replicating rare variants like the AA-specific *LRRC37A5P* variant is a known challenge, especially since rare variants tend to be population-specific [63]. To further interrogate rare loci identified in populations thus far underrepresented in GWAS, there must be a continued effort to increase the ancestral diversity of the populations studied in GWAS and all biomedical research.

In summary, this study of glycaemic traits in the diverse PAGE Study identified three novel fasting insulin loci: one AA-specific rare fasting glucose locus; and two novel independent secondary signals at known fasting glucose and fasting insulin loci. These findings reinforce the need to conduct genetic association studies in participants of diverse backgrounds to yield new insights into the genetics of glycaemic traits.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The PAGE consortium thanks the staff and participants of all PAGE studies for their important contributions. The complete list of PAGE members can be found at <http://www.pagestudy.org/page-investigators/>. We thank the staff and participants of the ARIC study for their important contributions. More detail about the ARIC study may be found at: <https://sites.csc.unc.edu/aric/>. We thank the WHI investigators and staff for their dedication and the study participants for making the programme possible. Full listing of WHI investigators can be found at <https://www.whi.org/researchers/DocumentsWriteaPaper/WHIInvestigatorShortList.pdf>. We also thank the investigators, the staff and the participants of MESA for their valuable contributions. A full list of participating MESA institutions and investigators can be found at <http://www.mesa-nhlbi.org> and <https://www.mesa-nhlbi.org/aboutMESAPersonnel.aspx>, respectively. We also thank the staff and participants of CARDIA for their important contributions. More details about CARDIA may be found at: <https://www.cardia.dopm.uab.edu/>. Representatives of the National Institute of Neurological Disorders and Stroke were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of data. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at: <https://www.uab.edu/soph/regardsstudy/>. The authors wish to thank the staff and participants of the JHS. We also thank the National Institute for Nutrition and Health, China Center for Disease Control and Prevention, Beijing Municipal Center for Disease Control and Prevention, and the Chinese National Human Genome Center at Shanghai.

Funding

The PAGE Study is funded by the National Human Genome Research Institute with co-funding from the National Institute on Minority Health and Health Disparities. Assistance with data management, data integration, data dissemination, genotype imputation, ancestry deconvolution, population genetics, analysis pipelines and general study coordination was provided by the PAGE Coordinating Center (NIHU01HG007419). Genotyping services were provided by the Center for Inherited Disease Research, which is fully funded through a federal contract from the National Institutes of Health (NIH) to The Johns Hopkins University, contract number HHSN2682012000081. Genotype data quality control and quality assurance services were provided by the Genetic Analysis Center in the Biostatistics Department of the University of Washington, through support provided by the Center for Inherited Disease Research contract. PAGE data and materials included in this report were funded through the following studies and organisations:

1. The ARIC study is funded in whole or in part by federal funds from the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract nos HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL059367 and R01HL086694, National Human Genome Research Institute contract U01HG004402, and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by grant no. UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.
2. The Mount Sinai BioMe Biobank is supported by The Andrea and Charles Bronfman Philanthropies.
3. The CARDIA Study is supported by contracts HHSN268201800003I, HHSN268201800004I, HHSN268201800005I, HHSN268201800006I and HHSN268201800007I from the National Heart, Lung and Blood Institute (NHLBI). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between NIA and NHLBI (AG0005). GWAS genotyping and data analyses were funded in part by grants U01-HG004729 and R01-HL093029 from the National Institutes of Health to M. Fornage.
4. The MEC characterisation of epidemiological architecture is funded through the NHGRI PAGE programme (U01HG004802 and its NHGRI ARRA supplement). The MEC study is funded by the National Cancer Institute (R37CA54281, R01CA63, P01CA33619, U01CA136792 and U01CA98758).
5. The WHI programme is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, and US Department of Health and Human Services through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005.
6. The HCHS/SOL is a collaborative study supported by contracts from the National Heart, Lung and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), University of Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I / N01-HC 65235), University of Illinois at Chicago (HHSN268201300003I / N01-HC-65236 Northwestern University), and San Diego State University (HHSN268201300005I / N01-HC-65237). The following Institutes/Centres/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities; National Institute on Deafness and Other Communication Disorders; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Neurological Disorders and Stroke; and NIH Institution-Office of Dietary Supplements. The Genetic Analysis Center at the University of Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C AM03 and MOD03).
7. The JHS is supported and conducted in collaboration with Jackson State University (HHSN268201800013I), Tougaloo College (HHSN268201800014I), the Mississippi State Department of Health (HHSN268201800015I) and the University of Mississippi Medical Center (HHSN268201800010I, HHSN268201800011I and HHSN268201800012I) contracts from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities (NIMHD).
8. The REGARDS project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services.
9. MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079 and UL1-TR-001420. Funding for SHARe genotyping was provided by NHLBI contract N02-HL-64278. Genotyping was performed at Affymetrix (Santa Clara, CA, USA) and the Broad Institute of Harvard and MIT (Boston, MA, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
10. The CCHC is supported by MD000170 P20 funded from the National Center on Minority Health and Health Disparities (NCMHD), the University of Texas Houston Health Sciences Center, Center for Clinical and Translational Science CCTS-CTSA award UL1 TR00371 from NCATS.
11. The CHNS receives research grant funding from the National Institute for Health (NIH), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) for R01

HD30880, National Institute on Aging (NIA) for R01 AG065357, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for R01DK104371 and R01HL108427, the NIH Fogarty grant D43 TW009077 since 1989, and the China-Japan Friendship Hospital, Ministry of Health for support for CHNS 2009, Chinese National Human Genome Center at Shanghai since 2009, and Beijing Municipal Center for Disease Prevention and Control since 2011.

12. Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute (NHLBI) grant R01HL105756.

CLA, HMH, CGD, SFD, MG and KEN are supported by R01HL142825. HMH is also funded by NHLBI training grants T32 HL007055 and T32 HL129982-03, and ADA grant no. 1-19-PDF-045. KEN is also supported by R01HG010297-01. LMR is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant KL2T2002490 and by R01HG010297. JEB and HGP are supported by R01HL142302-01; HGP is also supported by U01HG007416. CK is supported by S10OD028685. RJFL is supported by R01HG010297 and R01HL151152. MRI is supported by R01HL136666. SB and TCM are supported by U01HG007419. LSP is supported by Veterans Administration (VA) awards CSP no. 2008, I01 CX001899, I01 CX001737 and HSR&D IIR 07-138, and by NIH awards R21 DK099716, R18 DK066204, R03 AI133172, R21 AI156161, U01 DK091958, U01 DK098246 and UL1 TR002378.

The study sponsors/funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.

Authors' relationships and activities

HMH receives a stipend from the American Heart Association for serving as a statistical editor for the journal *Circulation Research*. SAB has a financial interest in Adaptive Biotechnologies. LSP has served on Scientific Advisory Boards for Janssen, and has or had research support from Merck, Pfizer, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, AbbVie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline and the Cystic Fibrosis Foundation. LSP is also a cofounder and Officer and Board member and stockholder for a company, Diasyst, Inc., which markets software aimed to help improve diabetes management. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Data availability

Full summary statistics from each of the population-specific and transethnic results are available at NHGRI-EBI GWAS catalog (<https://www.ebi.ac.uk/gwas/downloads/summary-statistics>).

Abbreviations

AA	African American
ARIC	Atherosclerosis Risk in Communities
ASN	Asian
CARDIA	Coronary Artery Risk Development in Young Adults Study
CCHC	Cameron County Hispanic Cohort
CHNS	China Health and Nutrition Survey
CS	Credible set
DHS	DNase I hypersensitive sites
EA	European
GS	Glycogen synthase

GWAS	Genome-wide association studies
HA	Hispanic/Latino
HCHS/SOL	Hispanic Community Health Study/Study of Latinos
HI	Native Hawaiian
JHS	Jackson Heart Study
LD	Linkage disequilibrium
MAF	Minor allele frequency
MAGIC	Meta-Analyses of Glucose and Insulin-related traits Consortium
MEC	Multiethnic Cohort
MESA	Multi-Ethnic Study of Atherosclerosis
NA_m	Native American
PAGE	Population Architecture using Genomics and Epidemiology
PPP1R3B	Protein phosphatase 1 regulatory subunit 3B
REGARDS	Reasons for Geographical and Racial Differences in Stroke
WHI	Women's Health Initiative

References

1. Cowie C, Casagrande S, Geiss L (2018) Prevalence and incidence of type 2 diabetes and prediabetes. In: Cowie C, Casagrande S, Menke A et al. (eds) *Diabetes in America: 3rd edition*, vol 17–1468. National Institutes of Health, Bethesda, MD
2. Tancredi M, Rosengren A, Svensson AM et al. (2015) Excess mortality among persons with type 2 diabetes. *N Engl J Med* 373(18):1720–1732. 10.1056/NEJMoa1504347 [PubMed: 26510021]
3. Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S (2017) Diabetes 2030: insights from yesterday, today, and future trends. *Popul Health Manag* 20(1):6–12. 10.1089/pop.2015.0181 [PubMed: 27124621]
4. Huang ES, Basu A, O'Grady M, Capretta JC (2009) Projecting the future diabetes population size and related costs for the U.S. *Diabetes Care* 32(12):2225–2229. 10.2337/dc09-0459 [PubMed: 19940225]
5. Dupuis J, Langenberg C, Prokopenko I et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* 42(2):105–116. 10.1038/ng.520 [PubMed: 20081858]
6. Manning AK, Hivert MF, Scott RA et al. (2012) A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycaemic traits and insulin resistance. *Nat Genet* 44(6):659–669. 10.1038/ng.2274 [PubMed: 22581228]
7. Wheeler E, Leong A, Liu CT et al. (2017) Impact of common genetic determinants of hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis. *PLoS Med* 14(9):e1002383. 10.1371/journal.pmed.1002383 [PubMed: 28898252]
8. Prasad RB, Groop L (2015) Genetics of type 2 diabetes-pitfalls and possibilities. *Genes (Basel)* 6(1):87–123. 10.3390/genes6010087 [PubMed: 25774817]

9. Scott RA, Scott LJ, Magi R et al. (2017) An expanded genome-wide association study of type 2 diabetes in Europeans. *Diabetes* 66(11): 2888–2902. 10.2337/db16-1253 [PubMed: 28566273]
10. Prokopenko I, Langenberg C, Florez JC et al. (2009) Variants in MTNR1B influence fasting glucose levels. *Nat Genet* 41(1):77–81. 10.1038/ng.290 [PubMed: 19060907]
11. Scott RA, Lagou V, Welch RP et al. (2012) Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat Genet* 44(9): 991–1005. 10.1038/ng.2385 [PubMed: 22885924]
12. Haiman CA, Fesinmeyer MD, Spencer KL et al. (2012) Consistent directions of effect for established type 2 diabetes risk variants across populations: the Population Architecture Using Genomics and Epidemiology (PAGE) Consortium. *Diabetes* 61(6):1642–1647. 10.2337/db11-1296 [PubMed: 22474029]
13. Fesinmeyer MD, Meigs JB, North KE et al. (2013) Genetic variants associated with fasting glucose and insulin concentrations in an ethnically diverse population: results from the Population Architecture Using Genomics and Epidemiology (PAGE) study. *BMC Med Genet* 14:98. 10.1186/1471-2350-14-98 [PubMed: 24063630]
14. Bien SA, Pankow JS, Haessler J et al. (2017) Transethnic insight into the genetics of glycaemic traits: fine-mapping results from the Population Architecture Using Genomics and Epidemiology (PAGE) consortium. *Diabetologia* 60(12):2384–2398. 10.1007/s00125-017-4405-1 [PubMed: 28905132]
15. Liu CT, Raghavan S, Maruthur N et al. (2016) Trans-ethnic Meta-analysis and functional annotation illuminates the genetic architecture of fasting glucose and insulin. *Am J Hum Genet* 99(1):56–75. 10.1016/j.ajhg.2016.05.006 [PubMed: 27321945]
16. Sigma Type 2 Diabetes Consortium, Estrada K, Aukrust I et al. (2014) Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. *Jama* 311(22):2305–2314. 10.1001/jama.2014.6511 [PubMed: 24915262]
17. Moltke I, Grarup N, Jorgensen ME et al. (2014) A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. *Nature* 512(7513):190–193. 10.1038/nature13425 [PubMed: 25043022]
18. Manning A, Highland HM, Gasser J et al. (2017) A low-frequency inactivating AKT2 variant enriched in the Finnish population is associated with fasting insulin levels and type 2 diabetes risk. *Diabetes* 66(7):2019–2032. 10.2337/db16-1329 [PubMed: 28341696]
19. Zaitlen N, Pasaniuc B, Gur T, Ziv E, Halperin E (2010) Leveraging genetic variability across populations for the identification of causal variants. *Am J Hum Genet* 86(1):23–33. 10.1016/j.ajhg.2009.11.016 [PubMed: 20085711]
20. Ong RT, Wang X, Liu X, Teo YY (2012) Efficiency of trans-ethnic genome-wide meta-analysis and fine-mapping. *Eur J Hum Genet* 20(12):1300–1307. 10.1038/ejhg.2012.88 [PubMed: 22617345]
21. Teo YY, Ong RT, Sim X, Tai ES, Chia KS (2010) Identifying candidate causal variants via trans-population fine-mapping. *Genet Epidemiol* 34(7):653–664. 10.1002/gepi.20522 [PubMed: 20839287]
22. DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium et al. (2014) Genome-wide transancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet* 46(3):234–244. 10.1038/ng.2897 [PubMed: 24509480]
23. Matisse TC, Ambite JL, Buyske S et al. (2011) The next PAGE in understanding complex traits: design for the analysis of population architecture using genetics and epidemiology (PAGE) study. *Am J Epidemiol* 174(7):849–859. 10.1093/aje/kwr160 [PubMed: 21836165]
24. International Expert Committee (2009) International expert committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 32(7):1327–1334. 10.2337/dc09-9033 [PubMed: 19502545]
25. Bien SA, Wojcik GL, Zubair N et al. (2016) Strategies for enriching variant coverage in candidate disease loci on a multiethnic genotyping Array. *PLoS One* 11(12):e0167758. 10.1371/journal.pone.0167758 [PubMed: 27973554]

26. Wojcik GL, Graff M, Nishimura KK et al. (2019) Genetic analyses of diverse populations improves discovery for complex traits. *Nature* 570(7762):514–518. 10.1038/s41586-019-1310-4 [PubMed: 31217584]
27. Lin DY, Tao R, Kalsbeek WD et al. (2014) Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos. *Am J Hum Genet* 95(6):675–688. 10.1016/j.ajhg.2014.11.005 [PubMed: 25480034]
28. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26(17):2190–2191. 10.1093/bioinformatics/btq340 [PubMed: 20616382]
29. Benner C, Spencer CC, Havulinna AS, Salomaa V, Ripatti S, Pirinen M (2016) FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics* 32(10):1493–1501. 10.1093/bioinformatics/btw018 [PubMed: 26773131]
30. Pruim RJ, Welch RP, Sanna S et al. (2010) LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 26(18):2336–2337. 10.1093/bioinformatics/btq419 [PubMed: 20634204]
31. Spracklen CN, Shi J, Vadlamudi S et al. (2018) Identification and functional analysis of glycemic trait loci in the China Health and Nutrition Survey. *PLoS Genet* 14(4):e1007275. 10.1371/journal.pgen.1007275 [PubMed: 29621232]
32. Lagou V, Magi R, Hottenga JJ et al. (2021) Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. *Nat Commun* 12(1):24. 10.1038/s41467-020-19366-9 [PubMed: 33402679]
33. Nolte IM (2020) Metasubtract: an R-package to analytically produce leave-one-out meta-analysis GWAS summary statistics. *Bioinformatics* 36(16):4521–4522. 10.1093/bioinformatics/btaa570 [PubMed: 32696040]
34. Miguel-Escalada I, Bonas-Guarch S, Cebola I et al. (2019) Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. *Nat Genet* 51(7):1137–1148. 10.1038/s41588-019-0457-0 [PubMed: 31253982]
35. Pasquali L, Gaulton KJ, Rodriguez-Segui SA et al. (2014) Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. *Nat Genet* 46(2):136–143. 10.1038/ng.2870 [PubMed: 24413736]
36. Ramos-Rodriguez M, Raurell-Vila H, Colli ML et al. (2019) The impact of proinflammatory cytokines on the beta-cell regulatory landscape provides insights into the genetics of type 1 diabetes. *Nat Genet* 51(11):1588–1595. 10.1038/s41588-019-0524-6 [PubMed: 31676868]
37. Carithers LJ, Moore HM (2015) The Genotype-Tissue Expression (GTEx) Project. *Biopreserv Biobank* 13(5):307–308. 10.1089/bio.2015.29031.hmm [PubMed: 26484569]
38. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W et al. (2015) Integrative analysis of 111 reference human epigenomes. *Nature* 518(7539):317–330. 10.1038/nature14248 [PubMed: 25693563]
39. Chen J, Spracklen CN, Marenne G et al. (2021) The trans-ancestral genomic architecture of glycemic traits. *Nat Genet* 53(6):840–860. 10.1038/s41588-021-00852-9 [PubMed: 34059833]
40. GTEx Consortium (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 348(6235):648–660. 10.1126/science.1262110 [PubMed: 25954001]
41. Vujkovic M, Keaton JM, Lynch JA et al. (2020) Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* 52(7):680–691. 10.1038/s41588-020-0637-y [PubMed: 32541925]
42. Heid IM, Jackson AU, Randall JC et al. (2010) Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat Genet* 42(11):949–960. 10.1038/ng.685 [PubMed: 20935629]
43. Zhu Z, Guo Y, Shi H et al. (2020) Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. *J Allergy Clin Immunol* 145(2):537–54. 10.1016/j.jaci.2019.09.035 [PubMed: 31669095]
44. Vuckovic D, Bao EL, Akbari P et al. (2020) The polygenic and monogenic basis of blood traits and diseases. *Cell* 182(5):1214–1231 e1211. 10.1016/j.cell.2020.08.008 [PubMed: 32888494]

45. Astle WJ, Elding H, Jiang T et al. (2016) The allelic landscape of human blood cell trait variation and links to common complex disease. *Cell* 167(5):1415–1429 e1419. 10.1016/j.cell.2016.10.042 [PubMed: 27863252]
46. Staels W, Heremans Y, Heimberg H, De Leu N (2019) VEGF-A and blood vessels: a beta cell perspective. *Diabetologia* 62(11): 1961–1968. 10.1007/s00125-019-4969-z [PubMed: 31414144]
47. Ng MCY, Graff M, Lu Y et al. (2017) Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. *PLoS Genet* 13(4):e1006719. 10.1371/journal.pgen.1006719 [PubMed: 28430825]
48. Li YZ, Di Cristofano A, Woo M (2020) Metabolic role of PTEN in insulin signaling and resistance. *Cold Spring Harb Perspect Med* 10(8):a036137. 10.1101/cshperspect.a036137 [PubMed: 31964643]
49. Spracklen CN, Horikoshi M, Kim YJ et al. (2020) Identification of type 2 diabetes loci in 433,540 East Asian individuals. *Nature* 582(7811):240–245. 10.1038/s41586-020-2263-3 [PubMed: 32499647]
50. Willems EL, Wan JY, Norden-Krichmar TM, Edwards KL, Santorico SA (2020) Transethnic meta-analysis of metabolic syndrome in a multiethnic study. *Genet Epidemiol* 44(1):16–25. 10.1002/gepi.22267 [PubMed: 31647587]
51. Ying W, Wollam J, Ofrecio JM et al. (2017) Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling. *J Clin Invest* 127(3):1019–1030. 10.1172/JCI90350 [PubMed: 28192375]
52. Esmaili S, George J (2015) Ltb4r1 inhibitor: a pivotal insulin sensitizer? *Trends Endocrinol Metab* 26(5):221–222. 10.1016/j.tem.2015.03.007 [PubMed: 25858788]
53. Li Q, Zhao Q, Zhang J et al. (2019) The protein phosphatase 1 complex is a direct target of AKT that links insulin signaling to hepatic glycogen deposition. *Cell Rep* 28(13):3406–3422 e3407. 10.1016/j.celrep.2019.08.066 [PubMed: 31553910]
54. Niazi RK, Sun J, Have CT et al. (2019) Increased frequency of rare missense PPP1R3B variants among Danish patients with type 2 diabetes. *PLoS One* 14(1):e0210114. 10.1371/journal.pone.0210114 [PubMed: 30629617]
55. Rose CS, Ek J, Urhammer SA et al. (2005) A –30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. *Diabetes* 54(10):3026–3031. 10.2337/diabetes.54.10.3026 [PubMed: 16186409]
56. Hwang JY, Sim X, Wu Y et al. (2015) Genome-wide association meta-analysis identifies novel variants associated with fasting plasma glucose in East Asians. *Diabetes* 64(1):291–298. 10.2337/db14-0563 [PubMed: 25187374]
57. Horikoshi M, Mgi R, van de Bunt M et al. (2015) Discovery and fine-mapping of glycaemic and obesity-related trait loci using high-density imputation. *PLoS Genet* 11(7):e1005230. 10.1371/journal.pgen.1005230 [PubMed: 26132169]
58. Suzuki K, Akiyama M, Ishigaki K et al. (2019) Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. *Nat Genet* 51(3):379–386. 10.1038/s41588-018-0332-4 [PubMed: 30718926]
59. Osbak KK, Colclough K, Saint-Martin C et al. (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. *Hum Mutat* 30(11):1512–1526. 10.1002/humu.21110 [PubMed: 19790256]
60. Bell GI, Polonsky KS (2001) Diabetes mellitus and genetically programmed defects in beta-cell function. *Nature* 414(6865):788–791. 10.1038/414788a [PubMed: 11742410]
61. Kim SH (2015) Maturity-onset diabetes of the young: what do clinicians need to know? *Diabetes Metab J* 39(6):468–477. 10.4093/dmj.2015.39.6.468 [PubMed: 26706916]
62. Huffman JE (2018) Examining the current standards for genetic discovery and replication in the era of mega-biobanks. *Nat Commun* 9(1):5054. 10.1038/s41467-018-07348-x [PubMed: 30498205]
63. Bodmer W, Bonilla C (2008) Common and rare variants in multi-factorial susceptibility to common diseases. *Nat Genet* 40(6):695–701. 10.1038/ng.f.136 [PubMed: 18509313]

Research in context

What is already known about this subject?

- Previous genome-wide association studies (GWAS) have identified over 500 loci associated with type 2 diabetes, and glycaemic and insulin-related traits
- Most of these findings were generated in populations of European ancestry

What is the key question?

- Can novel primary loci and independent secondary signals associated with fasting glucose, fasting insulin and HbA_{1c} be identified in transethnic and population-specific meta-analyses in the diverse Population Architecture using Genomics and Epidemiology (PAGE) Study?

What are the new findings?

- We identified three novel fasting insulin loci in transethnic meta-analysis, and a novel low-frequency African American-specific locus
- We also identified two novel independent secondary signals in known fasting glucose and fasting insulin loci

How might this impact on clinical practice in the foreseeable future?

- These findings provide new insights into the genetic architecture of glycaemic traits and highlight the importance of conducting genetic studies in diverse populations




Fig. 1. Manhattan plots for glycaemic trait association analyses in PAGE, adjusting for BMI. **(a)** Fasting insulin transethnic meta-analysis results. **(b)** HbA_{1c} transethnic meta-analysis results. **(c)** Fasting glucose transethnic meta-analysis results. **(d)** Fasting glucose AA-specific meta-analysis results. Known loci are shown in grey; novel loci with p value $< 1 \times 10^{-6}$ are shown in purple; novel loci with p value $< 5 \times 10^{-9}$ are shown in pink




Fig. 2. Forest plots of primary GWAS and replication transesthetic and population-specific meta-analysis effect estimates and 95% CIs for the four novel variants identified in the PAGE Study. **(a)** Fasting glucose variant rs571025315 at *LRRC37A5P* locus, which was genome-wide significant ($p < 5 \times 10^{-9}$) only in AA-specific meta-analysis. Effective $n < 30$ for all other populations in the primary analysis, indicated by sample size $n = NA$ in the primary analysis panel. **(b)** Fasting insulin variant rs9472142 at *VEGFA* locus. **(c)** Fasting insulin variant rs35131928 at *CASC8/CASC21* locus; EA REGARDS replication data used proxy variant rs10956361 in lieu of rs35131928 ($D' = 1$ and $r^2 = 1$ with rs35131928 in EA PAGE data). **(d)** Fasting insulin variant rs10887773 at *PTEN* locus. PAGE Study GWAS results for transesthetic and population-specific meta-analyses are shown against a white background; transesthetic and population-specific meta-analyses of replication results are shown against a grey background. Replication data sources, by population, are as follows: AA, JHS, REGARDS; EA, REGARDS, MESA, MAGIC; HA, MESA, CCHC; and ASN, MESA, CHNS

Table 2

Significant ($p < 5 \times 10^{-8}$) previously unreported secondary signals at known fasting insulin and fasting glucose loci

Trait	Secondary Variant ^a	Chr:Position	Ref allele	Alt allele	Locus	Effect (SE) of alt allele in conditional analysis	Primary analysis transethnic p value ^b	Conditional analysis transethnic p value ^c	Primary conditioning variant(s) ^d	LD D^e	LD r^2 ^f	MAF						
												Transethnic	AA	EA	HA	ASN	HI	NAM
Fasting insulin	rs330941	8:9018657	C	T	<i>PPP1R3B</i>	0.045 (0.007)	4.79×10^{-7}	2.37×10^{-10}	rs4841132	0.18	0.005	0.43	0.29	0.39	0.49	0.22	0.27	0.43
Fasting glucose	rs55908146	7:44180226	G	A	<i>GCK/ MYL7</i>	0.043 (0.008)	8.03×10^{-6}	1.75×10^{-8}	rs2908286, rs2908290	0.04, 0.24	0.001, 0.014	0.28	0.15	0.32	0.30	0.26	0.25	0.30

^aLead variant from conditional analysis reaching locus-specific significance

^b p value of the secondary variant in the primary GWAS analysis, not adjusted for the primary variant

^c p value of the secondary variant, adjusted for the primary variant(s)

^dLead variant(s) from the primary analysis and previous stepwise conditional analysis

^eLD D' between primary variant(s) and secondary variant in PAGE Study data (transethnic LD generated from unrelated subset of AA, HA, ASN, HI and NAM participants)

^fLD r^2 between primary variant(s) and secondary variant in PAGE Study data (transethnic LD generated from unrelated subset of AA, HA, ASN, HI and NAM participants)

Fine-mapping posterior probabilities of k causal variants at novel primary GWAS and independent secondary signal loci

Table 3

Trait	GWAS index variant	Locus	Posterior probability (no. of causal variants is k)				
			$k=1$	$k=2$	$k=3$	$k=4$	$k=5$
Primary GWAS analysis loci							
Fasting glucose	rs571025325	<i>LRRRC37A5P</i>	0.62	0.38	4.74×10^{-7}	0	0
Fasting insulin	rs9472142	<i>VEGFA</i>	0.37	0.48	0.15	0.01	0
Fasting insulin	rs35131928	<i>CASC8/CASC21</i>	0.72	0.28	0.0002	0	0
Fasting insulin	rs10887773	<i>PTEN</i>	0.78	0.22	0	0	0
Conditional analysis loci							
Fasting insulin	rs330941	<i>PPP1R3B</i>	0.05	0.77	0.19	0	0
Fasting glucose	rs55908146	<i>GCK/MYL7</i>	0	0.04	0.37	0.54	0.06